A Study to Learn More About Prevenar 20 Once it is Out in the Korean Market
Recruiting
Observational Study
Pneumococcal Immunization
Safety
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 6 Weeks and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 660 (estimated)
- Sponsor
- Pfizer · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The purpose of this study is to understand the safety of Prevenar 20 (Pneumococcal 20-valent conjugate vaccine) once it is out in the Korean market. Prevenar 20 will be given to participants aged 6 weeks or older in Republic of Korea.
This study is seeking for participants who are:
* Infant, children and adolescents aged 6 weeks to under 18 years or adult who are 18 years or older
* Prescribed P…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
Subjects must meet all of the following inclusion criteria to be eligible for inclusion in the study:
1. Infant, children and adolescents who are aged 6 weeks to under 18 years or adult who are 18 years or older
2. Subjects who have been prescribed Prevenar 20 by their physicia…
Contacts